Program
Lenalidomide
Also written as “lenalidomide”, “CC-5013” and “Drug: Carfilzomib + Lenalidomide + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 6 companies.
Drug pageLenalidomide: every studyMany companies study it; this page follows only the 78 they lead. All 751 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 670 open or running | phase 3since Mar 5, 2003 | Aug 16, 2002 | none ahead |
| Takedaits history only | 50 open or running | phase 4since May 30, 2017 | Jul 25, 2007 | none ahead |
| Oncotherapeuticsits history only | 32 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| bionor-immuno-as | 10 open or running | phase 2since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Samyang Biopharmaceuticalsits history only | 10 open or running | phase 1since Jun 25, 2017 | Jun 25, 2017 | none ahead |
| starton-therapeutics-incits history only | 11 open or running | phase 2since Sep 20, 2023 | Sep 20, 2023 | May 31, 2027phase 2 · NCT06087653 |
Also a collaborator on its studies: AbbVie, Prologue Research International, Karyopharm Therapeutics, Incyte, Johnson & Johnson, Abbott, ICON Clinical Research and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of bionor-immuno-as only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2012First study: phase 2 study in InfectionsFirst studyNCT01704781 · 36 enrolled · Germany
TargetBeta
“CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
Studies
The one study bionor-immuno-as leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01704781Infections · Germany | 2 | Completed | Aug 2014 | 36 |
How it is read
Names in the registry
- “Lenalidomide”, 67 entries
- “lenalidomide”, 16 entries
- “CC-5013”, 14 entries
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
- “Tafasitamab plus lenalidomide”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 45 studies
- Lymphoma, Large B-Cell, Diffuse, 10 studies
- Myelodysplastic Syndromes, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Lymphoma, Mantle-Cell, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.